Drugs / ampreloxetine
ampreloxetine
also known as
TD-9855 · Ampreloxetina · AMPRELOXETINE HYDROCHLORIDE · Ampreloxetine monohydrochloride · TD-9855 HCl · TD-9855 MONOHYDROCHLORIDE
Small molecule targets SLC6A2 via inhibition
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04688632 | Jan → Mar 2021 | nanophthalmos 3, orthostatic hypotension | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT04200573 | Jan 2020 → Aug 2021 | orthostatic hypotension | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT03432793 | Feb → Apr 2018 | — | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT01924143 | Oct → Nov 2013 | attention deficit-hyperactivity disorder, fibromyalgia | Theravance Biopharma | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02705755 | Sep 2017 → Jul 2018 | Parkinson disease, orthostatic hypotension, pure autonomic failure | Theravance Biopharma | Completed | No outcome recorded |
| Phase 2 | NCT01693692 | Nov 2012 → Jan 2014 | fibromyalgia | Theravance Biopharma | Completed | No outcome recorded |
| Phase 2 | NCT01458340 | Dec 2011 → Oct 2013 | attention deficit-hyperactivity disorder | Theravance Biopharma | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04095793 | Sep 2019 → Nov 2021 | orthostatic hypotension | Theravance Biopharma | Terminated | No outcome recorded |
| Phase 3 | NCT03829657 | Feb 2019 → Nov 2021 | Parkinson disease, orthostatic hypotension, pure autonomic failure | Theravance Biopharma | Terminated | No outcome recorded |
| Phase 3 | NCT03750552 | Jan 2019 → Jul 2021 | orthostatic hypotension | Theravance Biopharma | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05696717 Comparator | Jun 2023 → Jan 2026 overdue | multiple system atrophy, orthostatic hypotension | Theravance Biopharma | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ampreloxetine | “Ampreloxetine, a selective norepinephrine reuptake inhibitor, increases circulating norepinephrine levels.” PMID 34657222 ↗ Oct 2021 |
| Known as | Ampreloxetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297646 ↗ |
| Known as | AMPRELOXETINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297646 ↗ |
| Known as | Ampreloxetine monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297646 ↗ |
| Known as | TD-9855 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02705755 ↗ |
| Known as | TD-9855 HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297646 ↗ |
| Known as | TD-9855 MONOHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297646 ↗ |
| Action | Inhibit | “The findings are consistent with long-lasting NET inhibition, which may increase vasoconstrictor tone, supporting once-daily ampreloxetine dosing in patients with nOH.” PMID 33782836 ↗ Mar 20211“Norepinephrine transporter inhibitor” CHEMBL4297646 ↗ |
| Modality | Small molecule | — CHEMBL4297646 ↗ |
| Route | Oral | “single oral dose” NCT01924143 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL4297646 ↗ |